Breast cancer cell response to calcitonin: modulation by growth-regulating agents.
Calcitonin may induce cyclic AMP production by breast cancer cells and inhibit their growth. The molecular complex leading to cyclic AMP production in response to calcitonin is made of the calcitonin receptor coupled to the adenylate cyclase by at least one guanine nucleotide-binding protein (G-protein, of the Gs type). Our aim was to determine whether and how the responses of cells to calcitonin were modulated by growth-regulating agents not directly acting through the cyclic AMP pathway. We found that the cyclic AMP response to calcitonin was reduced after preincubation of cells with the mitogens 17beta-estradiol and epidermal growth factor (EGF), while it was enhanced after preincubation with the growth inhibitors tamoxifen and 1,25(OH)2D3, as well as with an antisense oligonucleotide to the proto-oncogene c-myc. Scatchard-plots revealed no significant change in the calcitonin receptor number or affinity. On the other hand, the cyclic AMP production of cells in response to activators unrelated to calcitonin, such as forskolin, a direct adenylate cyclase effector, and isoproterenol, a beta-adrenergic receptor agonist, was modulated only weakly or not at all by the growth-regulating agents. This suggested that the effects observed were essentially calcitonin-specific and associated with events located between the calcitonin receptor and the adenylate cyclase. Since a Go- or Gi-protein has been previously implicated in the calcitonin signal transduction, we tested the action of pertussis toxin, a specific inhibitor of these G-proteins. Pertussis toxin produced a general increase in the cyclic AMP response of cells to calcitonin; moreover, the toxin almost abolished the effect of mitogens and antimitogens on that parameter. We conclude that in breast cancer cells, the calcitonin receptor and the adenylate cyclase are coupled by at least one Go/Gi-protein sensitive to growth-regulating agents; this results in a modulation of the cyclic AMP response to calcitonin by these agents. On the other hand, the growth-inhibitory effect of calcitonin on breast cancer cells was reduced by 17beta-estradiol and enhanced by tamoxifen. We suggest that this could be a consequence of changes in cyclic AMP levels and deserves further investigation.
Lacroix
M
M
Laboratoire d'Investigation Clinique et d'Oncologie Expérimentale H.J. Tagnon, Institut J. Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Siwek
B
B
Body
J J
JJ
D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D002116:Calcitonin / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D000242:Cyclic AMP / Q000032:analysis*; D004958:Estradiol / Q000494:pharmacology; D005260:Female; D006801:Humans; D000090063:Proto-Oncogene Mas; D018003:Receptors, Calcitonin / Q000378:metabolism; D013629:Tamoxifen / Q000494:pharmacology; D014407:Tumor Cells, Cultured / Q000187:drug effects
C000715470:MAS1 protein, human; D000090063:Proto-Oncogene Mas; D018003:Receptors, Calcitonin; D013629:Tamoxifen; D004958:Estradiol; D002116:Calcitonin; D000242:Cyclic AMP